Chemokine receptor antagonist and its combinational therapy
Номер патента: EP3125919A1
Опубликовано: 08-02-2017
Автор(ы): Beverly James Incledon, Qicheng David Yang, Yiu-Chung Lee
Принадлежит: Microconstants China Inc, Pertinax Therapeutics Inc
Опубликовано: 08-02-2017
Автор(ы): Beverly James Incledon, Qicheng David Yang, Yiu-Chung Lee
Принадлежит: Microconstants China Inc, Pertinax Therapeutics Inc
Реферат: A method for treating various types of cancer/tumor by administering the combination of SDF-1 antagonist, in particular, that specifically binds to human CXCR4, and another chemotherapeutic agent, or a radiation therapy, during an embolization therapy. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the method is particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone.
Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions
Номер патента: WO2003063846A3. Автор: Ellen G McMahon,Amy E Rudolph. Владелец: Amy E Rudolph. Дата публикации: 2003-12-04.